Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Guidelines in 2024: International Contributions from China

Jianbin Li; Zefei Jiang

doi:10.20892/j.issn.2095-3941.2024.0374

References

1.↵
2. Li J,
3. Hao C,
4. Wang K,
5. Zhang J,
6. Chen J,
7. Liu Y, et al.
Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024. Transl Breast Cancer Res. 2024; 5: 18.
OpenUrl PubMed
2.↵
2. Li J,
3. Zhou J,
4. Wang H,
5. Liu Z,
6. Fan Z,
7. Liu Y, et al.
Trends in disparities and transitions of treatment in patients with early breast cancer in China and the US, 2011 to 2021. JAMA Netw Open. 2023; 6: e2321388.
3.↵
2. Curigliano G,
3. Burstein HJ,
4. Gnant M,
5. Loibl S,
6. Cameron D,
7. Regan MM, et al.
Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023. Ann Oncol. 2023; 34: 970–86.
OpenUrl CrossRef PubMed
4.↵
2. Shao Z,
3. Pang D,
4. Yang H,
5. Li W,
6. Wang S,
7. Cui S, et al.
Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia: the PEONY Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020; 6: e193692.
5.↵
2. Wu S,
3. Bian L,
4. Wang H,
5. Zhang S,
6. Wang T,
7. Yu Z, et al.
De-escalation of neoadjuvant taxane and carboplatin therapy in HER2-positive breast cancer with dual HER2 blockade: a multicenter real-world experience in China. World J Surg Oncol. 2024; 22: 214.
OpenUrl PubMed
6.↵
2. Wu J,
3. Jiang Z,
4. Liu Z,
5. Yang B,
6. Yang H,
7. Tang J, et al.
Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial. BMC Med. 2022; 20: 498.
OpenUrl PubMed
7.↵
2. Ma F,
3. Yan M,
4. Li W,
5. Ouyang Q,
6. Tong Z,
7. Teng Y, et al.
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial. BMJ. 2023; 383: e076065.
8.↵
2. Yan M,
3. Bian L,
4. Hu X,
5. Zhang Q,
6. Ouyang Q,
7. Feng J, et al.
Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study. Transl Breast Cancer Res. 2020; 1: 13.
OpenUrl
9.↵
2. Xu B,
3. Yan M,
4. Ma F,
5. Hu X,
6. Feng J,
7. Ouyang Q, et al.
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021; 22: 351–60.
OpenUrl CrossRef PubMed
10.↵
2. Cortés J,
3. Kim SB,
4. Chung WP,
5. Im SA,
6. Park YH,
7. Hegg R, et al.
Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022; 386: 1143–54.
OpenUrl CrossRef PubMed
11.↵
2. Li F,
3. Xu F,
4. Li J,
5. Wang T,
6. Bian L,
7. Zhang S, et al.
Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study. Ann Transl Med. 2021; 9: 103.
OpenUrl PubMed
12.↵
2. Jiang Z,
3. Yu Z,
4. Geng C,
5. Lin Y,
6. Liu Z,
7. Fu P, et al.
Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin followed by adjuvant tislelizumab in patients with early triple-negative breast cancer. J Clin Oncol. 2023; 41(suppl 16): 602.
OpenUrl
13.↵
2. He M,
3. Hao S,
4. Ma L,
5. Xiu B,
6. Yang B,
7. Wang Z, et al.
Neoadjuvant anthracycline followed by toripalimab combined with nab-paclitaxel in patients with early triple-negative breast cancer (NeoTENNIS): a single-arm, phase II study. EClinicalMedicine. 2024; 74: 102700.
14.↵
2. Jiang Z,
3. Ouyang Q,
4. Sun T,
5. Zhang Q,
6. Teng Y,
7. Cui J, et al.
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Nat Med. 2024; 30: 249–56.
OpenUrl PubMed
15.↵
2. Mo H,
3. Yu Y,
4. Sun X,
5. Ge H,
6. Yu L,
7. Guan X, et al.
Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial. Nat Med. 2024; 30: 2528–39.
OpenUrl PubMed
16.↵
2. Wang K,
3. Yang J,
4. Wang B,
5. Liu Q,
6. Wang X,
7. Yin Y, et al.
Expert consensus on the clinical application of immunotherapy in breast cancer: 2024. Transl Breast Cancer Res. 2024; 5: 9.
OpenUrl PubMed
17.↵
2. Rastogi P,
3. O’Shaughnessy J,
4. Martin M,
5. Boyle F,
6. Cortes J,
7. Rugo HS, et al.
Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. J Clin Oncol. 2024; 42: 987–93.
OpenUrl CrossRef PubMed
18.↵
2. Slamon D,
3. Lipatov O,
4. Nowecki Z,
5. McAndrew N,
6. Kukielka-Budny B,
7. Stroyakovskiy D, et al.
Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. 2024; 390: 1080–91.
OpenUrl CrossRef PubMed
19.↵
2. Zhang QY,
3. Sun T,
4. Yin YM,
5. Li HP,
6. Yan M,
7. Tong ZS, et al.
MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2− advanced breast cancer: the multinational randomized phase III study. Ther Adv Med Oncol. 2020; 12: 1758835920963925.
20.↵
2. Xu B,
3. Zhang Q,
4. Zhang P,
5. Hu X,
6. Li W,
7. Tong Z, et al.
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nat Med. 2021; 27: 1904–9.
OpenUrl CrossRef PubMed
21.↵
2. Zhang P,
3. Zhang Q,
4. Tong Z,
5. Sun T,
6. Li W,
7. Ouyang Q, et al.
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2023; 24: 646–57.
OpenUrl PubMed
22.↵
2. Turner NC,
3. Oliveira M,
4. Howell SJ,
5. Dalenc F,
6. Cortes J,
7. Gomez Moreno HL, et al.
Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023; 388: 2058–70.
OpenUrl CrossRef PubMed
23.↵
2. Yuan Y,
3. Zhang S,
4. Wang T,
5. Wang B,
6. Wang S,
7. Shi J, et al.
Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR(+)HER2(−) metastatic breast cancer. Transl Breast Cancer Res. 2023; 4: 10.
OpenUrl PubMed
24.↵
2. Mosele F,
3. Deluche E,
4. Lusque A,
5. Le Bescond L,
6. Filleron T,
7. Pradat Y, et al.
Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat Med. 2023; 29: 2110–20.
OpenUrl PubMed
25.↵
2. Wolff AC,
3. Somerfield MR,
4. Dowsett M,
5. Hammond MEH,
6. Hayes DF,
7. McShane LM, et al.
Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists Guideline update. J Clin Oncol. 2023; 41: 3867–72.
OpenUrl CrossRef PubMed
26.↵
2. Li J,
3. Jiang Z.
Antibody drug conjugates in breast cancer in China: Highlights, challenges, and prospects. Cancer. 2023; 130(S8): 1371–7.
OpenUrl PubMed
27.↵
2. Zhang S,
3. Yin Y,
4. Xiong H,
5. Wang J,
6. Liu H,
7. Lu J, et al.
Efficacy, safety, and population pharmacokinetics of MW032 compared with denosumab for solid tumor-related bone metastases: a randomized, double-blind, phase 3 equivalence trial. JAMA Oncol 2024; 10: 448–55.
OpenUrl PubMed
28.↵
2. Li J,
3. Yuan Y,
4. Bian L,
5. Lin Q,
6. Yang H,
7. Ma L, et al.
A comparison between clinical decision support system and clinicians in breast cancer. Heliyon 2023; 9: e16059.

In this issue

Download PDF

Email Article

Citation Tools

Cited By...

Balancing global standards and regional nuances in breast cancer care: the role of guidelines, clinical research, precision medicine, and artificial intelligence in advancing quality of care for patients worldwide

Google Scholar

More in this TOC Section

Show more Editorial

Subjects

Breast cancer

[1] 1.↵

Li J,
Hao C,
Wang K,
Zhang J,
Chen J,
Liu Y, et al.
Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024. Transl Breast Cancer Res. 2024; 5: 18.
OpenUrl PubMed

[3] Li J,

[4] Hao C,

[5] Wang K,

[6] Zhang J,

[7] Chen J,

[8] Liu Y, et al.

[9] 2.↵

Li J,
Zhou J,
Wang H,
Liu Z,
Fan Z,
Liu Y, et al.
Trends in disparities and transitions of treatment in patients with early breast cancer in China and the US, 2011 to 2021. JAMA Netw Open. 2023; 6: e2321388.

[11] Li J,

[12] Zhou J,

[13] Wang H,

[14] Liu Z,

[15] Fan Z,

[16] Liu Y, et al.

[17] 3.↵

Curigliano G,
Burstein HJ,
Gnant M,
Loibl S,
Cameron D,
Regan MM, et al.
Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023. Ann Oncol. 2023; 34: 970–86.
OpenUrl CrossRef PubMed

[19] Curigliano G,

[20] Burstein HJ,

[21] Gnant M,

[22] Loibl S,

[23] Cameron D,

[24] Regan MM, et al.

[25] 4.↵

Shao Z,
Pang D,
Yang H,
Li W,
Wang S,
Cui S, et al.
Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia: the PEONY Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020; 6: e193692.

[27] Shao Z,

[28] Pang D,

[29] Yang H,

[30] Li W,

[31] Wang S,

[32] Cui S, et al.

[33] 5.↵

Wu S,
Bian L,
Wang H,
Zhang S,
Wang T,
Yu Z, et al.
De-escalation of neoadjuvant taxane and carboplatin therapy in HER2-positive breast cancer with dual HER2 blockade: a multicenter real-world experience in China. World J Surg Oncol. 2024; 22: 214.
OpenUrl PubMed

[35] Wu S,

[36] Bian L,

[37] Wang H,

[38] Zhang S,

[39] Wang T,

[40] Yu Z, et al.

[41] 6.↵

Wu J,
Jiang Z,
Liu Z,
Yang B,
Yang H,
Tang J, et al.
Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial. BMC Med. 2022; 20: 498.
OpenUrl PubMed

[43] Wu J,

[44] Jiang Z,

[45] Liu Z,

[46] Yang B,

[47] Yang H,

[48] Tang J, et al.

[49] 7.↵

Ma F,
Yan M,
Li W,
Ouyang Q,
Tong Z,
Teng Y, et al.
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial. BMJ. 2023; 383: e076065.

[51] Ma F,

[52] Yan M,

[53] Li W,

[54] Ouyang Q,

[55] Tong Z,

[56] Teng Y, et al.

[57] 8.↵

Yan M,
Bian L,
Hu X,
Zhang Q,
Ouyang Q,
Feng J, et al.
Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study. Transl Breast Cancer Res. 2020; 1: 13.
OpenUrl

[59] Yan M,

[60] Bian L,

[61] Hu X,

[62] Zhang Q,

[63] Ouyang Q,

[64] Feng J, et al.

[65] 9.↵

Xu B,
Yan M,
Ma F,
Hu X,
Feng J,
Ouyang Q, et al.
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021; 22: 351–60.
OpenUrl CrossRef PubMed

[67] Xu B,

[68] Yan M,

[69] Ma F,

[70] Hu X,

[71] Feng J,

[72] Ouyang Q, et al.

[73] 10.↵

Cortés J,
Kim SB,
Chung WP,
Im SA,
Park YH,
Hegg R, et al.
Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022; 386: 1143–54.
OpenUrl CrossRef PubMed

[75] Cortés J,

[76] Kim SB,

[77] Chung WP,

[78] Im SA,

[79] Park YH,

[80] Hegg R, et al.

[81] 11.↵

Li F,
Xu F,
Li J,
Wang T,
Bian L,
Zhang S, et al.
Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study. Ann Transl Med. 2021; 9: 103.
OpenUrl PubMed

[83] Li F,

[84] Xu F,

[85] Li J,

[86] Wang T,

[87] Bian L,

[88] Zhang S, et al.

[89] 12.↵

Jiang Z,
Yu Z,
Geng C,
Lin Y,
Liu Z,
Fu P, et al.
Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin followed by adjuvant tislelizumab in patients with early triple-negative breast cancer. J Clin Oncol. 2023; 41(suppl 16): 602.
OpenUrl

[91] Jiang Z,

[92] Yu Z,

[93] Geng C,

[94] Lin Y,

[95] Liu Z,

[96] Fu P, et al.

[97] 13.↵

He M,
Hao S,
Ma L,
Xiu B,
Yang B,
Wang Z, et al.
Neoadjuvant anthracycline followed by toripalimab combined with nab-paclitaxel in patients with early triple-negative breast cancer (NeoTENNIS): a single-arm, phase II study. EClinicalMedicine. 2024; 74: 102700.

[99] He M,

[100] Hao S,

[101] Ma L,

[102] Xiu B,

[103] Yang B,

[104] Wang Z, et al.

[105] 14.↵

Jiang Z,
Ouyang Q,
Sun T,
Zhang Q,
Teng Y,
Cui J, et al.
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Nat Med. 2024; 30: 249–56.
OpenUrl PubMed

[107] Jiang Z,

[108] Ouyang Q,

[109] Sun T,

[110] Zhang Q,

[111] Teng Y,

[112] Cui J, et al.

[113] 15.↵

Mo H,
Yu Y,
Sun X,
Ge H,
Yu L,
Guan X, et al.
Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial. Nat Med. 2024; 30: 2528–39.
OpenUrl PubMed

[115] Mo H,

[116] Yu Y,

[117] Sun X,

[118] Ge H,

[119] Yu L,

[120] Guan X, et al.

[121] 16.↵

Wang K,
Yang J,
Wang B,
Liu Q,
Wang X,
Yin Y, et al.
Expert consensus on the clinical application of immunotherapy in breast cancer: 2024. Transl Breast Cancer Res. 2024; 5: 9.
OpenUrl PubMed

[123] Wang K,

[124] Yang J,

[125] Wang B,

[126] Liu Q,

[127] Wang X,

[128] Yin Y, et al.

[129] 17.↵

Rastogi P,
O’Shaughnessy J,
Martin M,
Boyle F,
Cortes J,
Rugo HS, et al.
Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. J Clin Oncol. 2024; 42: 987–93.
OpenUrl CrossRef PubMed

[131] Rastogi P,

[132] O’Shaughnessy J,

[133] Martin M,

[134] Boyle F,

[135] Cortes J,

[136] Rugo HS, et al.

[137] 18.↵

Slamon D,
Lipatov O,
Nowecki Z,
McAndrew N,
Kukielka-Budny B,
Stroyakovskiy D, et al.
Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. 2024; 390: 1080–91.
OpenUrl CrossRef PubMed

[139] Slamon D,

[140] Lipatov O,

[141] Nowecki Z,

[142] McAndrew N,

[143] Kukielka-Budny B,

[144] Stroyakovskiy D, et al.

[145] 19.↵

Zhang QY,
Sun T,
Yin YM,
Li HP,
Yan M,
Tong ZS, et al.
MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2− advanced breast cancer: the multinational randomized phase III study. Ther Adv Med Oncol. 2020; 12: 1758835920963925.

[147] Zhang QY,

[148] Sun T,

[149] Yin YM,

[150] Li HP,

[151] Yan M,

[152] Tong ZS, et al.

[153] 20.↵

Xu B,
Zhang Q,
Zhang P,
Hu X,
Li W,
Tong Z, et al.
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nat Med. 2021; 27: 1904–9.
OpenUrl CrossRef PubMed

[155] Xu B,

[156] Zhang Q,

[157] Zhang P,

[158] Hu X,

[159] Li W,

[160] Tong Z, et al.

[161] 21.↵

Zhang P,
Zhang Q,
Tong Z,
Sun T,
Li W,
Ouyang Q, et al.
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2023; 24: 646–57.
OpenUrl PubMed

[163] Zhang P,

[164] Zhang Q,

[165] Tong Z,

[166] Sun T,

[167] Li W,

[168] Ouyang Q, et al.

[169] 22.↵

Turner NC,
Oliveira M,
Howell SJ,
Dalenc F,
Cortes J,
Gomez Moreno HL, et al.
Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023; 388: 2058–70.
OpenUrl CrossRef PubMed

[171] Turner NC,

[172] Oliveira M,

[173] Howell SJ,

[174] Dalenc F,

[175] Cortes J,

[176] Gomez Moreno HL, et al.

[177] 23.↵

Yuan Y,
Zhang S,
Wang T,
Wang B,
Wang S,
Shi J, et al.
Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR(+)HER2(−) metastatic breast cancer. Transl Breast Cancer Res. 2023; 4: 10.
OpenUrl PubMed

[179] Yuan Y,

[180] Zhang S,

[181] Wang T,

[182] Wang B,

[183] Wang S,

[184] Shi J, et al.

[185] 24.↵

Mosele F,
Deluche E,
Lusque A,
Le Bescond L,
Filleron T,
Pradat Y, et al.
Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat Med. 2023; 29: 2110–20.
OpenUrl PubMed

[187] Mosele F,

[188] Deluche E,

[189] Lusque A,

[190] Le Bescond L,

[191] Filleron T,

[192] Pradat Y, et al.

[193] 25.↵

Wolff AC,
Somerfield MR,
Dowsett M,
Hammond MEH,
Hayes DF,
McShane LM, et al.
Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists Guideline update. J Clin Oncol. 2023; 41: 3867–72.
OpenUrl CrossRef PubMed

[195] Wolff AC,

[196] Somerfield MR,

[197] Dowsett M,

[198] Hammond MEH,

[199] Hayes DF,

[200] McShane LM, et al.

[201] 26.↵

Li J,
Jiang Z.
Antibody drug conjugates in breast cancer in China: Highlights, challenges, and prospects. Cancer. 2023; 130(S8): 1371–7.
OpenUrl PubMed

[203] Li J,

[204] Jiang Z.

[205] 27.↵

Zhang S,
Yin Y,
Xiong H,
Wang J,
Liu H,
Lu J, et al.
Efficacy, safety, and population pharmacokinetics of MW032 compared with denosumab for solid tumor-related bone metastases: a randomized, double-blind, phase 3 equivalence trial. JAMA Oncol 2024; 10: 448–55.
OpenUrl PubMed

[207] Zhang S,

[208] Yin Y,

[209] Xiong H,

[210] Wang J,

[211] Liu H,

[212] Lu J, et al.

[213] 28.↵

Li J,
Yuan Y,
Bian L,
Lin Q,
Yang H,
Ma L, et al.
A comparison between clinical decision support system and clinicians in breast cancer. Heliyon 2023; 9: e16059.

[215] Li J,

[216] Yuan Y,

[217] Bian L,

[218] Lin Q,

[219] Yang H,

[220] Ma L, et al.

Main menu

User menu

Search

Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Guidelines in 2024: International Contributions from China

References

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Subjects

Navigate

More Information

For Authors

Journal Services

Main menu

User menu

Search

Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Guidelines in 2024: International Contributions from China

References

In this issue

Citation Manager Formats

Jump to section

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Subjects

Navigate

More Information

For Authors

Journal Services